Keywords: Vivus, Qsiva, Obesity treatment, EMA, MAA refused

EMA confirms negative view on Vivus' obesity drug Qsiva after appeal

Article | 22 February 2013

Print This

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) dealt a blow to US drugmaker Vivus (Nasdaq: ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in